**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 21, 2017

# AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

| Nevada | 001-37487 | 13-3632859 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

| 9635 Granite Ridge Drive, Suite 100<br>San Diego, California<br>(Address of principal executive offices) | 92123<br>(Zip Code) |
|---|---|

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

Today, June 21, 2017, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the “Company”), presented at the BIO International Convention. This presentation highlights certain significant and material events for the Company, including release of data regarding virus capture from our most recently concluded clinical study, as well as an update on planned initiation of government programs. A link to the presentation may be accessed on the Company’s website under the investor relations section of the website or at http://ir.aethlonmedical.com/ir-calendar/detail/2993/2017-bio-international-convention. The website address is www.aethlonmedical.com. No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS

| EXHIBIT NO. | DESCRIPTION |
|---|---|
| 99.1 | Presentation materials – BIO International Convention – June 21, 2017 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: June 21, 2017

**EXHIBIT INDEX**

| EXHIBIT NO. | DESCRIPTION |
| --- | --- |
| 99.1 | Presentation materials – BIO International Convention – June 21, 2017 |

Exhibit 99.1



*Image of Ebola viruses exiting host cells - Courtesy of NIAID*

# BIO INTERNATIONAL CONVENTION

JIM JOYCE - CHAIRMAN, CEO

NASDAQ - AEMD / JUNE 21, 2017

aethlon MEDICAL, INC.

# FORWARD LOOKING STATEMENTS

*The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com*

# TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE



aethlon MEDICAL, INC.

# TO SAVE LIVES

# THE TREATMENT OF LIFE-THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH ANTIVIRAL DRUGS

# HUMAN VIRUSES

## A SIGNIFICANT UNMET NEED IN GLOBAL HEALTH & BIODEFENSE

- ~300 VIRUSES ARE INFECTIOUS TO HUMANS
  - NINE (9) ARE ADDRESSED WITH AN APPROVED ANTIVIRAL DRUG AGENT
- 3-4 NEW HUMAN VIRUSES ARE IDENTIFIED EACH YEAR*
- GLOBAL WARMING, URBAN CROWDING AND TRANSCONTINENTAL TRAVEL ARE FUELING AN INCREASED EMERGENCE OF PANDEMIC VIRUS OUTBREAKS
  - I.E.: EBOLA, PANDEMIC INFLUENZA, MERS, SARS, YELLOW FEVER, ZIKA, ETC
- NO ANTIVIRAL STRATEGY TO ADDRESS UNKNOWN THREATS, INCLUDING VIRUSES ENGINEERED BY MAN AS AGENTS OF BIOTERRORISM

** Center for Immunity and Evolution, University of Edinburgh*

# OUR SOLUTION


*THE FIRST-IN-CLASS THERAPY TO BE ADVANCED IN FDA APPROVED STUDIES*

---

# THE HEMOPURIFIER®

## A BROAD-SPECTRUM TREATMENT COUNTERMEASURE

DESIGNED FOR THE SINGLE-USE REMOVAL OF VIRAL PATHOGENS FROM BLOOD

aethlon MEDICAL, INC.

---

# HEMOPURIFIER® ATTRIBUTES

- ELIMINATES VIRUSES FROM THE ENTIRE CIRCULATORY SYSTEM
- DEPLOYED ON ESTABLISHED GLOBAL INSTRUMENT NETWORK
- GLYCAN SHIELD (THE IMMUNE CLOAK) CAPTURE MECHANISM



*Image of HIV glycan shield in green*
*Courtesy of Oxford University*

# THE AETHLON HEMOPURIFIER®

FROM THEORETICAL CONCEPT TO CLINICAL REALITY



- >16 *IN VITRO* VIRUS CAPTURE STUDIES
- FOUR INVESTIGATIONAL HUMAN STUDIES (OUTSIDE U.S.)
- ~150 HUMAN TREATMENT EXPERIENCES
- ACHIEVED PRIMARY ENDPOINT IN FIRST FDA APPROVED STUDY

# The Aethlon Hemopurifier®

## Concluded FDA Approved Feasibility Study on March 13th, 2017

- Primary Objective: To Demonstrate Safety of the Hemopurifier® in health compromised individuals infected with a viral pathogen
  - End-Stage Renal disease subjects infected with hepatitis C virus (HCV)
  - A Model to advance the Hemopurifier® as a broad-spectrum Viral countermeasure
  - Conducted at DaVita Med Center Dialysis in Houston
    - Safety is the sole human challenge against virulent viral pathogens that do not permit for controlled clinical studies to be conducted
    - Study provides a pathway to conduct Pivotal studies against viruses that allow for controlled human studies
- **We achieved our primary objective - The Hemopurifier® was well tolerated with no device-related adverse events reported**



aethlon MEDICAL, INC.

# Feasibility Study Challenges To Overcome

- HEMOPURIFIER® MANUFACTURING DELAY
- REPLACEMENT OF PRINCIPAL INVESTIGATOR
- LACK OF SUBJECTS WHO MET STUDY INCLUSION-EXCLUSION CRITERIA




aethlon MEDICAL, INC.


*The Aethlon Hemopurifier®*
*Courtesy of Aethlon Medical*

*Hemopurifier® in vitro capture validations*

# Chronic & Latent Viruses

- ☑ Human Immunodeficiency Virus (HIV)
- ☑ Hepatitis C Virus (HCV)
- ☑ Cytomegalovirus (CMV)
- ☑ Epstein-Barr Virus (EBV)
- ☑ Herpes Simplex Virus-1 (HSV-1)





aethlon MEDICAL, INC.

*Hemopurifier® in vitro capture validations*

# Pandemic Influenza Viruses

- ☑ H1N1 Swine Flu
- ☑ H5N1 Bird Flu
- ☑ Spanish Flu of 1918 (reconstructed)

Actual Spanish Flu of 1918 pandemic resulted in approximately 50 million deaths worldwide.






aethlon MEDICAL, INC.

*Hemopurifier® in vitro capture validations*

# Mosquito-Borne Viruses

- ☑ Chikungunya
- ☑ Dengue
- ☑ West Nile
- ☑ Zika



aethlon MEDICAL, INC.

# Bioterror & Pandemic Threat Viruses

- ☑ Lassa
- ☑ MERS-CoV
- ☑ Smallpox (based on Monkeypox & Vaccinia models)
- ☑ Ebola



aethlon MEDICAL, INC.



*Ebola Image Courtesy of NIAID*

# Frankfurt University Hospital

EMERGENCY-USE APPROVAL FROM GERMANY'S FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES (BFARM) TO ADMINISTER HEMOPURIFIER® THERAPY TO AN EBOLA-INFECTED PHYSICIAN AT FRANKFURT UNIVERSITY HOSPITAL.



aethlon MEDICAL, INC.

# THE TREATMENT OF EBOLA VIRUS



A SINGLE 6.5-HOUR ADMINISTRATION OF HEMOPURIFIER® THERAPY WAS DELIVERED TO THE PATIENT, WHO WAS COMATOSE WITH MULTIPLE ORGAN FAILURE.



aethlon MEDICAL, INC.

# THE TREATMENT OF EBOLA VIRUS

DR. STEFAN BÜTTNER HOLDING THE HEMOPURIFIER® AFTER TREATMENT

# EBOLA TREATMENT RESULTS

PRESENTED AT THE AMERICAN SOCIETY OF NEPHROLOGY ANNUAL MEETING BY HELMUT GEIGER, M.D., CHIEF OF NEPHROLOGY AT FRANKFURT UNIVERSITY HOSPITAL

- HEMOPURIFIER® THERAPY WAS WELL TOLERATED WITH **NO** ADVERSE EVENTS
- PRE-TREATMENT VIRAL LOAD PRIOR WAS MEASURED TO BE **400,000 COPIES/ML**
- POST-TREATMENT VIRAL LOAD WAS MEASURED AT **1,000 COPIES/ML**
- VIRAL LOAD NEVER AGAIN ROSE ABOVE 1,000 COPIES/ML
- **PATIENT MADE A FULL RECOVERY**



aethlon MEDICAL, INC.

# HEMOPURIFIER® VIRUS CAPTURE ASSAY



- QUANTIFIES VIRUSES CAPTURED WITHIN THE HEMOPURIFIER® AND NO LONGER CIRCULATING IN THE PATIENT
- ASSAY REINFORCES SINGLE-USE REMOVAL OF VIRAL PATHOGENS LABEL INDICATION
- PROVIDES BETTER DEPICTION OF INFECTIOUS VS. NON-INFECTIOUS VIRUS CAPTURE
- ESTABLISHES AN ABSOLUTE VS. OBSERVATION DATAPOINT
- ASSAY DEVELOPMENT BEGAN DURING PREVIOUS HCV STUDIES
  - CONSISTENT CAPTURE OF 100 MILLION + VIRUSES



aethlon MEDICAL, INC.

# VIRUS CAPTURE ASSAY RESULT

**242 MILLION** COPIES OF EBOLA VIRUS CAPTURED WITHIN THE HEMOPURIFIER® DURING 6.5 HOUR TREATMENT

Analysis: BSL4 Lab
*Philipps University Marburg*
(O. Dolnik/M. Eickmann/S. Becker)


*The Aethlon Hemopurifier®*
*Courtesy of Aethlon Medical*

## VIRUS CAPTURE ASSAY RESULTS

### FDA FEASIBILITY STUDY

***Values measured post 500 ml/min high pressure 1-2 liter saline wash***

***A major deviation from our previous virus capture assay***

aethlon MEDICAL, INC.

*Values measured post 500 ml/min high pressure saline wash*

## DaVita Med Center Dialysis Virus Capture Study
**Houston, Texas USA / HCV-Infected ESRD Subjects / 4-Hour Treatment**

| Patient Cartridge Code | IU Capture Value | Total Virus Capture |
|---|---|---|
| 01-V1* | N/A | N/A |
| 01-V2 | $1.62 \times 10^9$ | 1,620,000,000 |
| 02-V1 | $3.99 \times 10^6$ | 3,990,000 |
| 02-V2 | $1.18 \times 10^7$ | 11,800,000 |

*Assay protocol deviation / improper storage and loss of elution fluid



aethlon MEDICAL, INC.

*Values measured post 500 ml/min high pressure wash*

| DaVita Med Center Dialysis Virus Capture Study<br>Houston, Texas USA / HCV-Infected ESRD Subjects / 4-Hour Treatment | | |
|---|---|---|
| Patient Cartridge Code | IU Capture Value | Total Virus Capture |
| 03-V1 | $1.38 \times 10^7$ | 13,800,000 |
| 03-V2 | $1.29 \times 10^7$ | 12,900,000 |
| 04-V1 | $1.24 \times 10^8$ | 124,000,000 |
| 04-V2 | $6.38 \times 10^7$ | 63,800,000 |
| 05-V1 | $4.19 \times 10^7$ | 41,900,000 |



aethlon MEDICAL, INC.

*Values measured post 500 ml/min high pressure saline wash*

| DaVita Med Center Dialysis Virus Capture Study<br>Houston, Texas USA / HCV-Infected ESRD Subjects / 4-Hour Treatment | | |
|---|---|---|
| Patient Cartridge Code | IU Capture Value | Total Virus Capture |
| 05-V2 | $7.10 \times 10^6$ | 7,100,000 |
| 06-V1 | $1.71 \times 10^6$ | 1,710,000 |
| 06-V2 | $5.89 \times 10^5$ | 589,000 |
| 07-V1 | $2.84 \times 10^6$ | 2,840,000 |
| 07-V2 | $1.03 \times 10^8$ | 103,000,000 |
| | Average Virus Capture | 154,418,000 |



aethlon MEDICAL, INC.


WHAT'S NEXT?

# The Aethlon Hemopurifier®

## NEXT STEPS - JULY 2017

- **Submitting Expedited Access Pathway (EAP)** application to FDA. Seeking **"Breakthrough Technology"** designation under 21st Century Cures Act
  - To speed the advancement of devices for unmet needs against life-threatening disease conditions for which no approved treatments exist
- **Launch BioDefense & Pandemic Threat Treatment Initiative with U.S. & Foreign Governments**
  - Specific to virulent viruses that do not permit for controlled human studies and whose capture by the Hemopurifier® has been validated
  - The Hemopurifier® Fulfills Current U.S. Government objectives to protect citizens from BioTerror and Pandemic threats
  - Goal is to be in the Strategic National Stockpile


DEPARTMENT OF HEALTH & HUMAN SERVICES · USA ·


ASPR
ASSISTANT SECRETARY FOR
PREPAREDNESS AND RESPONSE


FDA


CDC
CENTERS FOR DISEASE
CONTROL AND PREPARATION


UNITED STATES DEPARTMENT OF AGRICULTURE


NIH


U.S. DEPARTMENT OF
HOMELAND SECURITY


BIOMEDICAL ADVANCED RESEARCH
AND DEVELOPMENT AUTHORITY
BARDA


DEPARTMENT OF VETERANS AFFAIRS
UNITED STATES OF AMERICA


U.S. PUBLIC HEALTH SERVICE
1798


DEPARTMENT OF DEFENSE
UNITED STATES OF AMERICA

# MEETING THE PHEMCE OBJECTIVES

**PHEMCE goal is to procure medical countermeasures (MCMs) for the strategic national stockpile**

- ☑ PHEMCE seeks broad-spectrum MCMs that address high-priority threats and also have commercial viability in other medical applications
- ☑ Broad-spectrum approach to address both known and unknown threats
- ☑ Broad-spectrum MCM against emerging threats, including Ebola, Zika and MERS-CoV
- ☑ MCM against pandemic influenza, including non-pharmaceutical MCMs
- ☑ MCMs for at-risk children, pregnant women and older adults for whom first line treatment countermeasures are not recommended

# THE AETHLON HEMOPURIFIER®

## ALIGNS TO MEET U.S. PHEMCE GOALS & OBJECTIVES

# TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE



aethlon MEDICAL, INC.

# TO SAVE LIVES



aethlon MEDICAL, INC.

# THE TREATMENT OF LIFE-THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH ANTIVIRAL DRUGS


9635 Granite Ridge Drive, Suite 100
San Diego, California 92123
858.459.7800
Nasdaq: AEMD
www.AethlonMedical.com

*This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com*